We are live on ! Find out more
OMIC

Singular Genomics Systems, Inc. Common Stock

Delisted

OMIC was delisted on the 20th of February, 2025.

80 hedge funds and large institutions have $74.8M invested in Singular Genomics Systems, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

8% more funds holding

Funds holding: 7480 (+6)

10% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 21

25% less capital invested

Capital invested by funds: $99.2M → $74.8M (-$24.4M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
80
Holders Change
+6
Holders Change %
+8.11%
% of All Funds
1.29%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
19
Increased
23
Reduced
21
Closed
12
Calls
$10K
Puts
Net Calls
+$10K
Net Calls Change
+$10K

OMIC Hedge Fund Activity: Q4 2022 in Review

80 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q4 2022, worth a combined $74.8M — down 25% from $99.2M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new OMIC positions and 12 closed out — a net gain of 7 holders — while 23 added to existing stakes and 21 trimmed.

The largest buyer was Vanguard Group, adding an estimated $529K. The largest seller was Tikvah Management, cutting an estimated $2.23M.

  • 80 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q4 2022, up from 74 in Q3 2022.
  • Funds reported $74.8M of Singular Genomics Systems, Inc. Common Stock stock for Q4 2022, down 25% quarter-over-quarter.
  • 19 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q4 2022 and 12 closed out, a net change of +7 holders.
  • The largest Singular Genomics Systems, Inc. Common Stock buyer in Q4 2022 was Vanguard Group, an estimated $529K added.
  • The largest Singular Genomics Systems, Inc. Common Stock seller in Q4 2022 was Tikvah Management, an estimated $2.23M sold.

Based on aggregated 13F filings for Q4 2022.